Akari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing Strategic Partnership with WuXi XDC
Akari Therapeutics (AKTX) was downgraded by Maxim Group from "buy" to "hold".
Akari Therapeutics Announces Strategic Partnership with WuXi XDC to Advance Development of Its Novel ADC Payload Targeting RNA Splicing
Akari Therapeutics (AKTX) had its price target raised by HC Wainwright from $1.60 to $27.00. They now have a "buy" rating on the stock.
Akari Therapeutics Announces Abstract Accepted for Poster Presentation at the American Association for Cancer Research Annual Meeting 2026